サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1350672

薬剤耐性サーベイランスの世界市場 (～2028年)：ソリューション・用途・エンドユーザー別

Antimicrobial Resistance Surveillance Market by Solution, Application, End User - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 200 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
薬剤耐性サーベイランスの世界市場 (～2028年)：ソリューション・用途・エンドユーザー別
出版日: 2023年09月19日
発行: MarketsandMarkets
ページ情報: 英文 200 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の薬剤耐性サーベイランスの市場規模は、2023年の59億米ドルから、予測期間中は5.6%のCAGRで推移し、2028年には77億米ドルの規模に成長すると予測されています。

同市場の成長は、薬剤耐性病原体による感染症の蔓延、診断技術の革新、薬剤耐性の脅威の高まり、政府のイニシアチブの高まり、薬物乱用による多剤耐性の出現などの要因によってもたらされています。一方で、薬剤耐性診断システムやキットの高コスト性などの要因が同市場のさらなる成長を抑制しています。

ソリューション別で見ると、診断キットの部門が2023年に最大のシェアを示すと推定されています。同部門の大きなシェアは主に、早期発見・治療へのニーズの高まり、薬剤耐性に関する迅速診断の需要の増加、薬剤耐性動向のサーベイランスと追跡に不可欠なデータの必要性に起因しています。

用途別では、臨床診断の部門が2023年に最大のシェアを占めると推計されています。同部門の成長は、より良い患者転帰を求める傾向、薬剤耐性の蔓延などの要因に起因しています。

エンドユーザー別では、病院・診療所の部門が2023年に最大のシェアを示しています。病院・診療所における患者密度の高さ、病院内での院内感染の増加、感染制御プロトコルの維持などの要因が同市場の成長に寄与すると考えられています。

地域別では、北米が2023年に最大のシェアを占めると予測されています。同地域のシェアは、大手事業者の存在、薬剤耐性の最も高い普及率、強力な規制環境などに起因しています。

当レポートでは、世界の薬剤耐性サーベイランスの市場を調査し、市場概要、市場影響因子および市場機会の分析、技術の動向、ケーススタディ、法規制環境、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 技術分析
    • リアルタイムサーベイランスプラットフォーム
    • CRISPR-CASシステム
    • AIを活用したモバイルアプリケーション
  • 価格分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 関税と規制の分析
  • 特許分析
  • 主な会議とイベント
  • 貿易分析
  • 主要なステークホルダーと購入基準

第6章 薬剤耐性サーベイランス市場：ソリューション別

  • 診断キット
  • 診断システム
  • 監視および分析ソフトウェア
  • その他

第7章 薬剤耐性サーベイランス市場：用途別

  • 臨床診断
  • 公衆衛生監視
  • その他

第8章 薬剤耐性サーベイランス市場：エンドユーザー別

  • 病院・診療所
  • 研究および学術機関
  • その他

第9章 薬剤耐性サーベイランス市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 主要企業の採用戦略
  • 収益シェア分析
  • 市場シェア分析
  • 主要企業の企業評価マトリックス
  • スタートアップ/中小企業の企業評価マトリックス
  • 競合シナリオ

第11章 企業プロファイル

  • 主要企業
    • BIOMERIEUX SA
    • THERMO FISHER SCIENTIFIC INC.
    • BECTON, DICKINSON AND COMPANY
    • DANAHER CORPORATION
    • BIO-RAD LABORATORIES, INC.
    • LUMINEX CORPORATION
    • BRUKER CORPORATION
    • ROCHE DIAGNOSTICS
    • T2 BIOSYSTEMS, INC.
    • MERCK KGAA
    • ACCELERATE DIAGNOSTICS, INC.
    • BIOANALYSE
    • HIMEDIA LABORATORIES
    • LIOFILCHEM S.R.L.
    • ALIFAX S.R.L.
    • WOLTERS KLUWER N.V.
    • OPGEN, INC.
    • CREATIVE DIAGNOSTICS
    • SYNBIOSIS
  • その他の企業
    • ZHUHAI DL BIOTECH CO., LTD.
    • ELITECHGROUP
    • MAST GROUP LTD.
    • CONDALAB
    • GENEFLUIDICS, INC.
    • MP BIOMEDICALS

第12章 付録

目次
Product Code: BT 8787

The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. The growth in this market is driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, escalating threat of antimicrobial resistance, growing government initiatives to combat antimicrobial-resistance species, and emergence of multi-drug resistance due to drug abuse. On the other hand, factors such as high cost associated to antimicrobial resistance diagnostic systems and kits are limiting the growth of this market.

In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance market

By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the rising need for early detection and treatment, increasing demand for rapid diagnostics for antimicrobial resistance, and need of essential data for surveillance and tracking of antimicrobial resistance trends.

Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance market in 2023

By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications . In 2023, the clinical diagnostics segment is projected to account for the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing preference for better patient outcomes, and prevalence of antimicrobial resistance.

By end user, hospitals and clinics accounted for the largest share of the market

By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment accounted for the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the high patient density in hospitals and clinics, increasing nonsocomial infections in hospitals, and to maintain the infection control protocols.

By region, North America is projected to account for the largest share of the market

By region the global antimicrobial resistance surveillance segmented into-North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-40%, Tier 2-30%, and Tier 3-30%
  • By Designation - C-level-27%, Director-level-18%, Others-55%
  • By Region - North America-45%, Europe-15%, Asia Pacific-25%, and Middle East & Africa- 5%,ROW- 10%

Key players in the antimicrobial resistance surveillance Market

The prominent players in this market are Qiagen (Germany), Luminex Corporation (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Lumed (US), Wolters Kluwer N.V. (US), Abbott Laboratories (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Danaher (US), Bioanalyse (Turkey), Biomerieux (France), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), and Alifax S.r.l. (Italy).

Research Coverage:

The report analyzes the antimicrobial resistance surveillance Market and aims at estimating the market size and future growth potential of this market based on various segments such as solution, application and end user. The report also includes a product portfolio matrix of various antimicrobial resistance surveillance products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

Analysis of key drivers (growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies), restraints (high cost of antimicrobial resistance diagnostic systems/ kits), opportunities (growth opportunities in emerging countries and awareness initiatives for antimicrobial resistance and its control) and challenges (complex regulatory framework) influencing the growth of antimicrobial resistance surveillance market.

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global antimicrobial resistance surveillance Market. The report analyzes this market by solution, applications, and end user.
  • Service Enhancement/Innovation: Detailed insights on upcoming trends in the global antimicrobial resistance surveillance Market
  • Market Development: Comprehensive information on the lucrative emerging markets by solutions, applications, and end user.
  • Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global antimicrobial resistance surveillance Market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product and service offerings, company evaluation quadrant, and capabilities of leading players in the global antimicrobial resistance surveillance Market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
    • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 RECESSION IMPACT ON ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 BOTTOM-UP APPROACH
    • FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2023-2028)
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3 APPROACH USED TO DETERMINE IMPACT OF ECONOMIC RECESSION
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 8 MARKET DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET

4 PREMIUM INSIGHTS

  • 4.1 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OVERVIEW
    • FIGURE 13 GROWING PREVALENCE OF INFECTIONS CAUSED BY DRUG-RESISTANT PATHOGENS TO DRIVE MARKET GROWTH
  • 4.2 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION
    • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023-2028)
  • 4.3 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION AND COUNTRY (2022)
    • FIGURE 15 CLINICAL DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET IN 2022
  • 4.4 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: GEOGRAPHIC MIX
    • FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 17 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
    • FIGURE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.1.1 DRIVERS
      • 5.1.1.1 Growing prevalence of infections caused by drug-resistant pathogens
      • 5.1.1.2 Innovations in diagnostic technologies
      • 5.1.1.3 Growing government initiatives to combat antimicrobial-resistant species
      • 5.1.1.4 Emergence of multi-drug resistance due to drug abuse
    • 5.1.2 RESTRAINTS
      • 5.1.2.1 High cost of antimicrobial resistance diagnostic systems/kits
    • 5.1.3 OPPORTUNITIES
      • 5.1.3.1 Growth opportunities in emerging economies
      • 5.1.3.2 Awareness initiatives for antimicrobial resistance and control
    • 5.1.4 CHALLENGES
      • 5.1.4.1 Complex regulatory frameworks
  • 5.2 TECHNOLOGY ANALYSIS
    • 5.2.1 REAL-TIME SURVEILLANCE PLATFORMS
    • 5.2.2 CRISPR-CAS SYSTEMS
    • 5.2.3 AI-POWERED MOBILE APPLICATIONS
  • 5.3 PRICING ANALYSIS
    • 5.3.1 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
    • FIGURE 19 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
    • TABLE 3 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
    • 5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
    • TABLE 4 AVERAGE SELLING PRICE OF ANTIMICROBIAL RESISTANCE SURVEILLANCE SOLUTIONS, BY REGION
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 21 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: ECOSYSTEM MARKET MAP
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 TARIFF AND REGULATORY ANALYSIS
    • 5.8.1 TARIFF FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS
    • TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.8.2 REGULATORY ANALYSIS
      • 5.8.2.1 North America
        • 5.8.2.1.1 US
    • TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 8 US: TIME, COST, AND COMPLEXITY OF REGISTRATION
        • 5.8.2.1.2 Canada
    • TABLE 9 CANADA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 10 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION
      • 5.8.2.2 Europe
      • 5.8.2.3 Asia Pacific
        • 5.8.2.3.1 Japan
        • 5.8.2.3.2 China
    • TABLE 11 CHINA: MEDICAL DEVICE CLASSIFICATION
        • 5.8.2.3.3 India
  • 5.9 PATENT ANALYSIS
    • 5.9.1 PATENT PUBLICATION TRENDS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PRODUCTS
    • FIGURE 23 PATENT PUBLICATION TRENDS (JANUARY 2011-AUGUST 2023)
    • 5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 24 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (JANUARY 2011-AUGUST 2023)
    • FIGURE 25 TOP APPLICANTS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (COUNTRY/REGION) (JANUARY 2011-AUGUST 2023)
    • TABLE 12 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: LIST OF PATENTS (2020-2023)
  • 5.10 KEY CONFERENCES & EVENTS IN 2023-2024
    • TABLE 13 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DETAILED LIST OF CONFERENCES & EVENTS IN 2023-2024
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS
    • FIGURE 26 IMPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND)
    • FIGURE 27 EXPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND)
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS
    • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS (%)
    • 5.12.2 BUYING CRITERIA
    • FIGURE 29 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS
    • TABLE 15 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS

6 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION

  • 6.1 INTRODUCTION
    • TABLE 16 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
  • 6.2 DIAGNOSTIC KITS
    • 6.2.1 RISING AWARENESS OF AMR TO DRIVE MARKET GROWTH
    • TABLE 17 DIAGNOSTIC KITS OFFERED BY KEY PLAYERS
    • TABLE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC KITS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 DIAGNOSTIC SYSTEMS
    • 6.3.1 GROWING THREAT OF ANTIBIOTIC RESISTANCE TO ACCELERATE MARKET GROWTH
    • TABLE 19 DIAGNOSTIC SYSTEMS OFFERED BY KEY PLAYERS
    • TABLE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 SURVEILLANCE & ANALYTICS SOFTWARE
    • 6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
    • TABLE 21 SURVEILLANCE & ANALYTICS SOFTWARE OFFERED BY KEY PLAYERS
    • TABLE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR SURVEILLANCE & ANALYTICS SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 OTHER SOLUTIONS
    • TABLE 23 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER SOLUTIONS, BY COUNTRY, 2021-2028 (USD MILLION)

7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 24 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 CLINICAL DIAGNOSTICS
    • 7.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    • TABLE 25 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 PUBLIC HEALTH SURVEILLANCE
    • 7.3.1 GOVERNMENT INITIATIVES TO ACCELERATE MARKET GROWTH
    • TABLE 26 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 OTHER APPLICATIONS
    • TABLE 27 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 28 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS & CLINICS
    • 8.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    • TABLE 29 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 RESEARCH & ACADEMIC INSTITUTES
    • 8.3.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH
    • TABLE 30 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
    • TABLE 31 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER END USERS
    • TABLE 32 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 33 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 US to dominate North American market during forecast period
    • TABLE 38 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 39 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 40 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Favorable government initiatives to drive growth during forecast period
    • TABLE 41 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 42 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 43 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • TABLE 44 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany to dominate European market during forecast period
    • TABLE 48 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 49 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 50 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Significant prevalence of infectious diseases coupled with increasing awareness to drive market growth
    • TABLE 51 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 52 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 53 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Supportive government policies and easy accessibility to healthcare services to fuel growth
    • TABLE 54 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 55 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 56 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand
    • TABLE 57 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 58 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 59 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising geriatric population to drive market growth
    • TABLE 60 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 61 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 62 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 63 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 64 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 65 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.7 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT
    • TABLE 66 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Growing geriatric population to drive market
    • TABLE 70 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 71 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 72 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth
    • TABLE 73 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020
    • TABLE 74 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 75 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 76 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth
    • TABLE 77 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 78 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 79 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 80 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 81 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 82 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    • 9.5.1 GROWING ECONOMIC DEVELOPMENT TO DRIVE MARKET GROWTH
    • 9.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 83 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 84 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 85 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
    • 9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 86 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)
    • TABLE 87 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 88 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 89 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET
  • 10.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2018-2022)
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2022)
  • 10.5 COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS (2022)
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 34 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
    • 10.5.5 COMPANY FOOTPRINT
    • TABLE 90 COMPANY FOOTPRINT ANALYSIS, BY SOLUTION
    • TABLE 91 COMPANY FOOTPRINT ANALYSIS, BY APPLICATION
    • TABLE 92 COMPANY FOOTPRINT ANALYSIS, BY END USER
    • TABLE 93 COMPANY FOOTPRINT ANALYSIS, BY REGION
  • 10.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • FIGURE 35 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2022
    • 10.6.5 COMPETITIVE BENCHMARKING
    • TABLE 94 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY FOOTPRINT OF KEY PLAYERS
  • 10.7 COMPETITIVE SCENARIO
    • 10.7.1 PRODUCT LAUNCHES
    • TABLE 95 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020-SEPTEMBER 2023
    • 10.7.2 DEALS
    • TABLE 96 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEALS, JANUARY 2020-SEPTEMBER 2023

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats)**
    • 11.1.1 BIOMERIEUX SA
    • TABLE 97 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 36 BIOMERIEUX SA: COMPANY SNAPSHOT (2022)
    • 11.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 98 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 11.1.3 BECTON, DICKINSON AND COMPANY
    • TABLE 99 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 11.1.4 DANAHER CORPORATION
    • TABLE 100 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.5 BIO-RAD LABORATORIES, INC.
    • TABLE 101 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.6 LUMINEX CORPORATION
    • TABLE 102 LUMINEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 41 LUMINEX CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.7 BRUKER CORPORATION
    • TABLE 103 BRUKER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
    • 11.1.8 ROCHE DIAGNOSTICS (A DIVISION OF F-HOFFMAN-LA ROCHE LTD.)
    • TABLE 104 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 43 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022)
    • 11.1.9 T2 BIOSYSTEMS, INC.
    • TABLE 105 T2 BIOSYSTEMS, INC.: BUSINESS OVERVIEW
    • FIGURE 44 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.10 MERCK KGAA
    • TABLE 106 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 11.1.11 ACCELERATE DIAGNOSTICS, INC.
    • TABLE 107 ACCELERATE DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • FIGURE 46 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.12 BIOANALYSE
    • TABLE 108 BIOANALYSE: BUSINESS OVERVIEW
    • 11.1.13 HIMEDIA LABORATORIES
    • TABLE 109 HIMEDIA LABORATORIES: BUSINESS OVERVIEW
    • 11.1.14 LIOFILCHEM S.R.L.
    • TABLE 110 LIOFILCHEM S.R.L.: BUSINESS OVERVIEW
    • 11.1.15 ALIFAX S.R.L.
    • TABLE 111 ALIFAX S.R.L.: BUSINESS OVERVIEW
    • 11.1.16 WOLTERS KLUWER N.V.
    • TABLE 112 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW
    • FIGURE 47 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2022)
    • 11.1.17 OPGEN, INC.
    • TABLE 113 OPGEN, INC.: BUSINESS OVERVIEW
    • FIGURE 48 OPGEN, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.18 CREATIVE DIAGNOSTICS
    • TABLE 114 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
    • 11.1.19 SYNBIOSIS
    • TABLE 115 SYNBIOSIS: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 ZHUHAI DL BIOTECH CO., LTD.
    • 11.2.2 ELITECHGROUP
    • 11.2.3 MAST GROUP LTD.
    • 11.2.4 CONDALAB
    • 11.2.5 GENEFLUIDICS, INC.
    • 11.2.6 MP BIOMEDICALS
  • *Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS